Akari Therapeutics Plc Beta
Was ist das Beta von Akari Therapeutics Plc?
Beta von Akari Therapeutics Plc ist 0.00
Was ist die Definition von Beta?
BETA gibt an, ob eine Aktie mehr oder weniger schwankungsanfällig ist als der Gesamtmarkt. Ein Beta von weniger als 1 zeigt an, dass die Aktie weniger schwankungsanfällig ist als der Markt, während ein Beta von mehr als 1 anzeigt, dass die Aktie mehr schwankungsanfällig ist. Die Schwankungsanfälligkeit wird als Schwankung des Preises um den Mittelwert gemessen.
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
Beta von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Akari Therapeutics Plc
Was macht Akari Therapeutics Plc?
akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.
Unternehmen mit beta ähnlich Akari Therapeutics Plc
- Vision Marine Technologies hat Beta von 0.00
- Ely Gold Royalties hat Beta von 0.00
- Glacier Lake Resources hat Beta von 0.00
- Magnum Mining and Exploration hat Beta von 0.00
- Africa Opportunity Fund hat Beta von 0.00
- Fulcrum Utility Services hat Beta von 0.00
- Akari Therapeutics Plc hat Beta von 0.00
- Gullewa hat Beta von 0.00
- S.A.L. Steel hat Beta von 0.00
- Andina Acquisition III hat Beta von 0.00
- Andina Acquisition III hat Beta von 0.00
- Brilliant Acquisition hat Beta von 0.00
- Indokem hat Beta von 0.00